MARK IRWIN GREENE
Medical Practice in Penn Valley, PA
License number
Pennsylvania MD033875E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Penn Valley, PA 19072
Personal information
See more information about MARK IRWIN GREENE at radaris.comName
Address
Phone
500 Chestnut St, Mayfield, PA 18433
545 Rasley Hill Rd, Bangor, PA 18013
35 Burnside Ave, Bradford, PA 16701
326 S 3Rd St, Harrisburg, PA 17104
125 Talgrath Ct, Exton, PA 19341
Professional information
Prevention Of Tumors With Monoclonal Antibodies Against Neu
US Patent:
6733752, May 11, 2004
Filed:
Nov 20, 1995
Appl. No.:
08/525800
Inventors:
Mark I. Greene - Penn Valley PA
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 39395
US Classification:
4241301, 4241331, 4241411, 4241551, 4241561, 3503871, 3503873, 3503877, 3503881
Abstract:
Prevention of transformation of a normal cell into a tumour cell in an individual at risk of developing a tumour having tumours which have p185 on their surfaces comprises: (a) identifying the individual and (b) administering to the individual an antibody which specifically binds to p185. Also claimed is a method of preventing transformation of a normal cell into a tumour cell that has p185 on its surface in an individual who has had a tumour that has p185 on its cell surfaces removed or who has had a cancer characterised by tumour cells that have p185 on their surfaces enter remission, comprising (a) identifying the individual and (b) administering to the individual an antibody which specifically binds to p185.
Methods And Use Of Compounds That Bind To Her2/Neu Receptor Complex
US Patent:
2013013, May 30, 2013
Filed:
May 26, 2011
Appl. No.:
13/700915
Inventors:
Mark I. Greene - Penn Valley PA, US
Ramachandran Murali - Beverly Hills CA, US
Hongtao Zhang - Paoli PA, US
Ramachandran Murali - Beverly Hills CA, US
Hongtao Zhang - Paoli PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 31/165, A61K 45/06
US Classification:
514614
Abstract:
This application describes pharmaceutical compositions, commercial packages, and methods for inhibiting cell proliferative disorders, especially those disorders, including Her2 related cancers, characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, and methods for imaging an HER-2 expressing tumor.
Prevention Of Tumors With Monoclonal Antibodies Against Neu
US Patent:
2011027, Nov 10, 2011
Filed:
Jul 19, 2011
Appl. No.:
13/186299
Inventors:
Mark I. Greene - Penn Valley PA, US
Makoto Katsumata - Bryn Mawr PA, US
Jeffrey Drebin - St. Louis MO, US
Makoto Katsumata - Bryn Mawr PA, US
Jeffrey Drebin - St. Louis MO, US
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241331, 4241381
Abstract:
Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed.
Biologically Active Compounds And Methods Of Constructing And Using The Same
US Patent:
5637677, Jun 10, 1997
Filed:
Sep 3, 1992
Appl. No.:
7/940654
Inventors:
Mark I. Greene - Penn Valley PA
William V. Williams - Havertown PA
David B. Weiner - Merion PA
Jeffrey A. Cohen - Bala Cynwyd PA
Thomas Kieber-Emmons - Newtown Square PA
Robert M. Williams - Fort Collins CO
William V. Williams - Havertown PA
David B. Weiner - Merion PA
Jeffrey A. Cohen - Bala Cynwyd PA
Thomas Kieber-Emmons - Newtown Square PA
Robert M. Williams - Fort Collins CO
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
The Wistar Institute - Philadelphia PA
Colorado State University - Fort Collins CO
The Wistar Institute - Philadelphia PA
Colorado State University - Fort Collins CO
International Classification:
C07K 700, C07K 1414
US Classification:
530333
Abstract:
A method of constructing biologically active compounds which mimic the biological activity of the biologically active protein or which block the activity of the biologically active protein is disclosed. A method of identifying specific and discrete portions of pathogen antigens which either serve as epitopes for neutralizing antibodies or which are involved in pathogen binding to host cell receptors is disclosed. A method of constructing biologically active compounds which compete with cellular receptors for binding to either biologically active proteins or pathogen antigens is disclosed.
Method Of Stimulating Myelination Of Cells
US Patent:
5219837, Jun 15, 1993
Filed:
Jun 21, 1990
Appl. No.:
7/541779
Inventors:
Jeffrey A. Cohen - Bala Cynwyd PA
Mark I. Greene - Penn Valley PA
William V. Williams - Havertown PA
Mark I. Greene - Penn Valley PA
William V. Williams - Havertown PA
Assignee:
Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 3702, C07K 706, C07K 708
US Classification:
514 12
Abstract:
The present invention provides methods for treating mammalian diseases and conditions characterized by myelin destruction. The present invention provides methods for inducing myelin formation by myelin forming cells expressing reovirus type 3 receptors comprising administering to such cells an effective amount of a compound bindable with the reovirus type 3 receptor. The compounds for use in the method of the invention preferably comprise antibodies and peptides, more preferably synthetic peptides.
Methods Of Inhibiting Osteoclast Activity
US Patent:
7566741, Jul 28, 2009
Filed:
Jul 22, 2003
Appl. No.:
10/625073
Inventors:
Mark I. Greene - Penn Valley PA, US
Ramachandran Murali - Drexel Hill PA, US
Masahiko Kinosaki - Kaminokawa-machi, JP
Ramachandran Murali - Drexel Hill PA, US
Masahiko Kinosaki - Kaminokawa-machi, JP
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 31/05, A61K 31/03, A61K 31/085, A61K 31/131, A61P 19/08, A61P 19/10
US Classification:
514765, 514771, 435 4, 435183
Abstract:
Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.
Erbb Interface Peptidomimetics And Methods Of Use Thereof
US Patent:
8057799, Nov 15, 2011
Filed:
Nov 25, 2009
Appl. No.:
12/625706
Inventors:
Mark I. Greene - Penn Valley PA, US
Ramachandran Murali - Drexel Hill PA, US
Hongtao Zhang - Paoli PA, US
Mark Richter - Philadelphia PA, US
Alan Berezov - Glenolden PA, US
Qingdu Liu - Bala Cynwyd PA, US
Jinqiu Chen - Philadelphia PA, US
Ramachandran Murali - Drexel Hill PA, US
Hongtao Zhang - Paoli PA, US
Mark Richter - Philadelphia PA, US
Alan Berezov - Glenolden PA, US
Qingdu Liu - Bala Cynwyd PA, US
Jinqiu Chen - Philadelphia PA, US
Assignee:
The Trustees Of The University Of Pennsylvania - Philadelphia PA
International Classification:
A61K 39/00
US Classification:
4241841
Abstract:
Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.
Erbb Interface Peptidomimetics And Methods Of Use Thereof
US Patent:
7781566, Aug 24, 2010
Filed:
Nov 25, 2009
Appl. No.:
12/625650
Inventors:
Mark I. Greene - Penn Valley PA, US
Ramachandran Murali - Drexel Hill PA, US
Hongtao Zhang - Paoli PA, US
Mark Richter - Philadelphia PA, US
Alan Berezov - Glenolden PA, US
Qingdu Liu - Bala Cynwyd PA, US
Jinqiu Chen - Philadelphia PA, US
Ramachandran Murali - Drexel Hill PA, US
Hongtao Zhang - Paoli PA, US
Mark Richter - Philadelphia PA, US
Alan Berezov - Glenolden PA, US
Qingdu Liu - Bala Cynwyd PA, US
Jinqiu Chen - Philadelphia PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 38/00, C07K 14/00
US Classification:
530300, 530350
Abstract:
Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.
Methods And Use Of Compounds That Bind To Her2/Neu Receptor Complex
US Patent:
2013019, Jul 25, 2013
Filed:
May 26, 2011
Appl. No.:
13/700906
Inventors:
Mark I. Greene - Penn Valley PA, US
Ramachandran Murali - Beverly Hills CA, US
Hongtao Zhang - Paoli PA, US
Ramachandran Murali - Beverly Hills CA, US
Hongtao Zhang - Paoli PA, US
Assignee:
The Trustees of The University of Pennsylvania - Philadelphia PA
International Classification:
A61K 31/15, A61K 31/17, A61K 45/06
US Classification:
514585, 514641
Abstract:
This application describes pharmaceutical compositions, kits, and methods for inhibiting cell proliferative disorders, especially those disorders characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, including Her2 related cancers, and methods for imaging an Her-2 expressing tumor.
Cavity Induced Allosteric Modification Of Intermolecular Interactions And Methods Of Identifying Compounds That Effect The Same
US Patent:
2011031, Dec 22, 2011
Filed:
Jul 29, 2011
Appl. No.:
13/194832
Inventors:
Ramachandran Murali - Swarthmore PA, US
Mark I. Greene - Penn Valley PA, US
Mark I. Greene - Penn Valley PA, US
International Classification:
A61K 31/655, A61K 31/17, A61P 29/00, A61P 25/00, A61P 3/10, A61P 1/16, A61P 19/02, A61P 17/00, A61P 17/06, A61P 9/00, A61P 7/06, A61P 11/06, A61K 31/40, A61P 37/06
US Classification:
514150, 514423, 514597
Abstract:
Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed.